Prime Medicine Reports Q2 2026 Results with WD IND Clearances and New AATD IND Target
Prime Medicine secured global regulatory clearance for its Wilson disease program. The company also reported a favorable arbitration outcome for its Alpha-1 Antitrypsin Deficiency rights and provided updated financial guidance, highlighting progress towards a potential BLA submis
View filing at SEC.gov →